Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury

MT Newswires Live

07/24

Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.

The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.

The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.

The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653166706"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653166706\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653166706?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653166706","market":"hk","top_or_hot":-1,"title":"Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury","media":"MT Newswires Live","content":"<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKringle Pharma Starts Additional Phase Three Study on Oremepermin Alfa as Treatment for Acute Spinal Cord Injury\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-24 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.</p><p>The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.</p><p>The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.</p><p>The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653166706","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653166706","pubTimestamp":1784871689,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kringle Pharma  has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury , according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4192":"特殊消费者服务","LU1892829315.USD":"FIDELITY FUNDS SUSTAINABLE WATER & WASTE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","SCI":"Service Corp International","SCI.AU":"Silver City Minerals Ltd"},"translate_title":"Kringle Pharma 启动 Oremepermin Alfa 治疗急性脊髓损伤的额外三期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCI.AU":1,"SCI":1},"content_text":"Kringle Pharma (TYO:4884) has begun an additional phase three clinical study in Japan testing oremepermin alfa as a treatment for patients with acute spinal cord injury (SCI), according to a Friday filing.The biopharmaceutical company plans to enroll 10 patients diagnosed with AIS grade A cervical SCI across three national SCI hospitals.The company's primary endpoint is the proportion of patients with improved neurological status to AIS grade C or better after six months.The additional phase three study includes refined eligibility criteria that enrich responders, with exclusion of patients with severe structural spinal cord damage on magnetic resonance imaging.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}